Can skyrizi be used for psoriatic arthritis?

What is Skyrizi and how does it work for psoriatic arthritis?

Skyrizi (risankizumab) is a medication approved by the FDA for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. It is a humanized monoclonal antibody that targets the interleukin-23 (IL-23) protein, which plays a key role in inflammation and immune response. By blocking IL-23, Skyrizi reduces inflammation and slows down disease progression.

Can Skyrizi be used for psoriatic arthritis?

Yes, Skyrizi is approved for the treatment of active psoriatic arthritis in adults. Studies have shown that Skyrizi can significantly reduce signs and symptoms of psoriatic arthritis, such as joint pain, swelling, and stiffness. The medication has also been shown to slow down joint damage and improve quality of life.

How does Skyrizi compare with other treatments for psoriatic arthritis?

Skyrizi is a biologic medication, which means it is a protein-based treatment that targets specific molecules involved in inflammation and immune response. Other biologic treatments for psoriatic arthritis include Humira (adalimumab), Enbrel (etanercept), and Stelara (ustekinumab). Compared to these treatments, Skyrizi has been shown to have similar efficacy in reducing inflammation and slowing down disease progression, but may have a different side effect profile [1].

What are the potential side effects of Skyrizi for psoriatic arthritis?

Common side effects of Skyrizi include upper respiratory tract infections, headache, and fatigue. More serious side effects may include increased risk of infections, such as tuberculosis and herpes zoster, as well as malignancies, including lymphoma. Patients taking Skyrizi should be monitored for any signs of infection or cancer [2].

How is Skyrizi administered and what is the dosing schedule?

Skyrizi is administered via injection every 4 weeks for the first 4 doses, followed by every 8 weeks for maintenance therapy. It is recommended to administer Skyrizi once a week for the first 28 days, then once every 4 weeks thereafter.

When does the patent for Skyrizi expire?

According to DrugPatentWatch.com, the Skyrizi patent expiries in 2029 [3]. However, generic or biosimilar versions of the medication may become available before then.

Sources:

[1] DrugPatentWatch.com, "Risankizumab (Skyrizi) - Psoriatic Arthritis"

[2] Skyrizi (risankizumab) Prescribing Information

[3] DrugPatentWatch.com, "Risankizumab (Skyrizi)"